Aveta Biomics

ABOUT AVETA BIOMICS

Built to extend the reach
of immunotherapy.

Aveta Biomics is a clinical-stage biotechnology company developing oral immunotherapies designed to extend the reach of immunotherapy across immune-cold and immune-hot tumors.

Explore Our Science Meet Our Leadership

WHAT AVETA DOES

Many oncology drugs are built around a target.
Aveta is built around the tumor ecosystem.

01◉

ORAL THERAPY

Designed around the body’s own immune regulation

02✹

REPROGRAM THE TUMOR ENVIRONMENT

Counter immune suppression upstream of checkpoints

03✣

COORDINATED ANTITUMOR IMMUNE RESPONSE

Enable immune activity across cold and hot tumors

WHY THIS WORK MATTERS

The measure of progress is
what treatment allows people to keep.

Cancer such as Head and neck cancer can affect the most human parts of daily life. Speaking, eating, smiling and connecting with others. That human reality remains at the center of why we do this work and our treatment is intended to not only treat active cancer and increase the lifespan but also preserve these most basic human needs and improve patients' health span.

A head and neck cancer patient talking with a family member

EXECUTIVE LEADERSHIP

Parag G. Mehta, PhDParag G. Mehta, PhDChief Executive OfficerView biography Selda Samakoglu, MD, PhDSelda Samakoglu, MD, PhDChief Medical OfficerView biography Luis Z. Avila, PhDLuis Z. Avila, PhDChief Scientific OfficerView biography David PageDavid PageChief Financial OfficerView biography Robert Charnas, PhDRobert Charnas, PhDSenior Vice President, Regulatory AffairsView biography Kevin ZikarasKevin ZikarasVice President, Clinical Operations and DevelopmentView biography Murat Budak, MD, PhDMurat Budak, MD, PhDMedical DirectorView biography

BOARD OF DIRECTORS

Parag G. Mehta, PhDParag G. Mehta, PhDBoard DirectorView biography Peter DolanPeter DolanBoard DirectorView biography Bharat Tewarie, MD, MBABharat Tewarie, MD, MBABoard DirectorView biography David PageDavid PageBoard DirectorView biography Thomas Rudolph, MDThomas Rudolph, MDBoard DirectorView biography

THE BOARD OF ADVISORS

Anastasia Tousimis, MD, FACS, MBAAnastasia Tousimis, MD, FACS, MBAScientific and Medical AdvisorView biography Sid Puram, MD, PhDSid Puram, MD, PhDScientific and Medical AdvisorView biography Andrew Sikora, MD, PhDAndrew Sikora, MD, PhDScientific and Medical AdvisorView biography Jonathan Schoenfeld, MD, MPHJonathan Schoenfeld, MD, MPHScientific and Medical AdvisorView biography Daniel L. Hartl, PhDDaniel L. Hartl, PhDScientific AdvisorView biography Eugene I. Shakhnovich, PhDEugene I. Shakhnovich, PhDScientific AdvisorView biography Ajay GuptaAjay GuptaExecutive AdvisorView biography Jan HagemeierJan HagemeierExecutive AdvisorView biography

Science-led. Clinically focused. Built to execute.

TRANSLATIONAL SCIENCEGLOBAL CLINICAL DEVELOPMENTREGULATORY & MANUFACTURING READINESS

Writing the next chapter of immuno-oncology

We welcome conversations with those who share our ambition to extend the reach of immunotherapy.

Partner With Us